Kovalizumab Dosage Guide

Crovalimab, an innovative complement C5 inhibitor, provides a new treatment option for patients with paroxysmal nocturnal hemoglobinuria (PNH) aged 13 years and older and weighing at least 40kg. PNH is a rare and serious blood disorder characterized by anemia, thrombosis, pancytopenia, and dark-colored urine due to excessive hemolysis. For patients showing symptoms of hemolysis and high disease activity, as well as patients who have been stably treated with other C5 inhibitors for at least 6 months, kovalizumab is undoubtedly a new treatment option worth looking forward to.

Specific dosing and administration guidelines need to be followed when using kovalizumab. At the beginning of treatment, patients receive a loading dose as an intravenous (IV) infusion. For patients weighing 40kg to 100kg, it is recommended to give 1000mg intravenously on the first day; while for patients weighing more than 100kg, 1500mg is required intravenously. Subsequently, patients will receive four additional weekly loading doses of 340 mg via subcutaneous (SUBQ) injection on days 2, 8, 15 and 22, regardless of body weight. Starting from the 29th day, the maintenance treatment phase is entered, and the drug is administered by subcutaneous injection once every 4 weeks. Patients between 40kg and 100kg are injected with 680mg each time, and patients above 100kg are injected with a dose of 1020mg each time.

For patients switching from another complement inhibitor, the first loading dose of kovalizumab should be given before the next scheduled complement inhibitor dose. If the patient misses a scheduled dose or part of a dose, the missed dose should be taken as soon as possible before the next scheduled dose and then continue as normal on the scheduled dosing day. It is important not to take two doses on the same day or take more than prescribed to make up for a missed dose.
Of course, the use of corvalizumab may also be associated with some side effects, including infusion-related reactions, viral infections, respiratory infections (such as lung infections), and type III allergic reactions, such as pain or swelling of the nose or throat. Patients should pay close attention to these reactions during treatment and communicate with their doctors in a timely manner.
In summary, kovalizumab provides a new treatment approach for PNH patients, and its clear usage and dosage guidelines and controllable side effects make it a valuable clinical treatment option.
Reference link: https://www.accessdata.fda.gov/drugsatfda docs/label/2024/761388s000lbl.pdf